Compositions and methods for treating peripheral vascular disease

• US 20030073626A1
• Filed: 03/05/2002
• Published: 04/17/2003
• Est. Priority Date: 04/30/1999
• Status: Active Grant

• Current Assignee: Astrazeneca Pharmaceuticals LP (Astrazeneca PLC)
• Original Assignee: Amylin Pharmaceuticals Incorporated (Bristol-Myers Squibb Company)
• Inventors: Coolidge, Thomas R., Hathaway, David R.
• Granted Patent: US 7,259,136 B2
• Time in Patent Office: Days
• US Class Current: 514/12
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/355 Tocopherols, e.g. vitamin E
• CPC Class Codes: A61K 31/70 Carbohydrates; Sugars; Derivatives thereof sorbitol A61K31/047
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61K 38/063 Glutathione
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/446 Superoxide dismutase (1.15)
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention relates to methods of treating intermittent claudication comprising administering glucagon-like peptide-1 (GLP-1) molecules to subjects suffering therefrom.

Claims

1. A method of treating or preventing intermittent claudication in a subject comprising the step of administering a therapeutically effective amount of GLP-1 molecule.

3. The method according to claim 1 or 2, wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH₂, GLP-4(7-37), and exendin-4.

4. The method according to claim 1 or 2, wherein the GLP-1 molecule is selected from the group consisting of GLP-1(7-36)NH₂ and GLP-1(9-36)NH₂.

5. The method according to claim 1 or 2, wherein the subject is also administered free radical scavengers.

6. The method according to claim 5, wherein the free radical scavenger is selected from the group consisting of glutathione, melatonin, Vitamin E, and superoxide dismutase.

7. The method according to claim 1 or 2, wherein the subject is also administered glucose.

8. The method according to claim 7, wherein the subject is also administered potassium.

9. The method according to claim 1 or 2, wherein the subject is suffering from PVD.

10. The method according to claim 1 or 2, wherein the subject is human.

11. The method according to claim 1 or 2, wherein the GLP-1 is administered by an infusion pump or by subcutaneous injection of a slow release formulation.

2. A method of treating or preventing skeletal muscle injury caused by ischemia and/or reperfusion in a subject comprising the step of administering a therapeutically effective amount of GLP-1 molecule.